Comparison of Serum and Plasma MMP-9 Level in Breast Cancer Patients
DOI:
https://doi.org/10.22100/jkh.v6i2.109Keywords:
Breast cancer, Matrix mataloproteinase-9, Plasma level, Serum levelAbstract
Introduction: Matrix metalloproteinase-9 (MMP-9) has recently been reported as a marker gene for several cancers. With respect to our previous results about this gene, in the present study we compare the correlation betweenthe plasma and serum MMP-9 levels and clinical features of breast cancer patients.
Methods: In this case-control study, 114breast cancer patients and 87 healthy controls were studded.MMP-9 level was quantitatively measured byzymography and Bio Rad kit (Bio-Rad, Richmond, CA).
Results: Plasma MMP-9 level wassignificantly elevated in breast cancer patients comparedwith the control subjects (P<0.001). Also there was a correlation between the plasma MMP-9 level and lymph node metastasis (OR, 3.4; P=0.019) and venous invasion (OR, 4.14; P=0.033) of the patients. There was no correlation between the serum MMP-9 level and lymphatic metastasis or venous invasion of the patients.
Conclusion: According to our findings, plasma MMP-9 level is a bettermarker than the serum MMP-9 level for early diagnosis of breast cancer metastasis.
References
Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274(31):21491-4.
la-aho R, Kahari VM. Collagenases in cancer. Biochimie 2005;87(3-4):273-86.
Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000;10(6):415-33.
Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2(3):161-74.
Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999;31(1):34-45.
Zucker S, Hymowitz M, Conner C, Zarrabi HM, Hurewitz AN, Matrisian L, et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci 1999;878:212-27.
Zucker S, Lysik RM, Zarrabi MH, Moll U. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 1993;53:140-6.
Hoikkala S, Paakko P, Soini Y, Makitaro R, Kinnula V, Turpeenniemi-Hujanen T. Tissue MMP-2/TIMP-2-complex are better prognostic factors than serum MMP-2, MMP-9 or TIMP-1 in stage I-III lung carcinoma. Cancer Lett 2006;236(1):125-32.
Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker. Int J Cancer 2005;116(1):422-7.
Shen KH, Chi CW, Lo SS, Kao HL, Lui WY, Wu CW. Serum matrix metalloproteinase-9 level associated with stromal reaction in patients with gastric cancer. Anticancer Res 2000;20(28): 1307-10.
Hayasaka A, Suzuki N, Fujimoto N, Iwama S, Fukuyama E, Kanda Y, et al. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 1996;24(5):1058-62.
Endo K, Maehara Y, Baba H, Yamamoto M, Tomisaki S, Watanabe A, et al. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res 1997;17(3):2253-8.
Torii A, Kodera Y, Uesaka K, Hirai T, Yasui K, Morimoto T, et al. Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Br J Surg 1997;84(1):133-6.
Decock J, Hendrickx W, Wildiers H, Christiaens MR, Neven P, Drijkoningen M, et al. Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/neu expression and other clinicopathological variables. Clin Exp Metastasis 2005;22(6):495-502.
Kirman I, Jain S, Cekic V, Belizon A, Balik E, Sylla P, et al. Altered plasma matrix metalloproteinase-9/tissue metalloproteinase-1 concentration during the early postoperative period in patients with colorectal cancer. Surg Endosc 2006;20(3):706-9.
Jung K. Serum or plasma: what kind of blood sample should be used to measure circulating matrix metalloproteinases and their inhibitors? J Neuroimmunol 2005;162(1-2):1-2.
Mannello F, Luchetti F, Canonico B, Papa S. Effect of anticoagulants and cell separation media as preanalytical determinants on zymographic analysis of plasma matrix metalloproteinases. Clin Chem 2003;49:1956-7.
Mannello F. Effects of blood collection methods on gelatin zymography of matrix metalloproteinases. Clin Chem 2003;49:339-40.
Jung K, Laube C, Lein M, Lichtinghagen R, Tschesche H, SchnorrD, et al. Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. Clin Chem 1998;44(5):1060-2.
Dragutinovic VV, Radovanovic NS, Izrael-Zivkovic LT, Vrvic MM. Detection of gelatinase B activity in serum of gastric cancer patients. World J Gastroenterol 2006;12(5):105-9.
Rauvala M, Puistola U, Turpeenniemi-Hujanen T. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol 2005;99(3):656-63.
Chen W, Abnet CC, Wei WQ, Roth MJ, Lu N, Taylor PR, et al. Serum markers as predictors of esophageal squamous dysplasia and early cancer. Anticancer Res 2004;24(5):3245-9.
Kodama S, Iwata K, Iwata H, Yamashita K, Hayakawa T. Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases. An application for rheumatoid arthritis serum and plasma. J Immunol Methods 1990;127(1):103-8.
Fujisawa T, Kato Y, Terada A, Iguchi K, Kamiya H. Matrix metalloproteinase-9 in peripheral blood eosinophils. Int Arch Allergy Immunol 1999;120:65-9.
Oberg A, Hoyhtya M, Tavelin B, Stenling R, Lindmark G. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 2000;20(2):1085-91.
Hrabec E, Strek M, Nowak D, Hrabec Z. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Respir Med 2001;95(1):1-4.
Yang SF, Hsieh YS, Lin CL, Hsu NY, Chiou HL, Chou FP, et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta 2005;354:91-9.
Tamura M, Oda M, Matsumoto I, Tsunezuka Y, Kawakami K, Ohta Y, et al. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer. Ann Surg Oncol 2004;11(10):928-33.
Stella Maris Ranuncolo, Eduardo Armanasco, Carlos Cresta 2, Elisa Bal de Kier Joffe , Lydia Puricelli. Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Internat J of Cancer 2003;106(5):745-751.
La Rocca G, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 2004;90(7):1414-21.
Somiari SB, Shriver CD, Heckman C, Olsen C, Hu H, Jordan R, et al. Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at high risk of developing breast cancer. Cancer Lett 2006; 233(1):98-107.
Mannello F, Tonti GA. Gelatinase concentrations and zymographic profiles in human breast cancer: Matrix metalloproteinases circulating in plasma are better markers for the subclassification and early prediction of cancer: The coagulation/fibrinolysis pathways alter the release, activation and recovery of different gelatinases in serum. Int J Cancer 2007;121(1):216-23.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
